PLSE News
Pulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid Center
Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation (nano-PFA or nsPFA) technology, today announced a partnership with the Clayman Thyroid Center at the Hospital for Endocrine Surgery in Tampa, Florida. The...
Business Wire
Pulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid Center
Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation (nano-PFA or nsPFA) technology, today announced a partnership with the Clayman Thyroid Center at the Hospital for Endocrine Surgery in Tampa, Florida. The...
Business Wire
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation (nano-PFA or nsPFA) technology, today announced that the Compensation Committee of its Board of Directors has granted equity awards to two new employees as equity...
Business Wire
Pulse Biosciences nPulse Technology to be Featured at the 21st Annual International VT Symposium 2026
Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation (nano-PFA or nsPFA) technology, today announced the latest nPulse technology advancement will be featured during the 21st Annual International Ventricular...
Business Wire
Pulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse Cardiac Catheter System for Atrial Fibrillation Treatment
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nano-PFA or nsPFA) technology, today announced that its NANOPULSE-AF Study has reached its enrollment target of 164 evaluable patients across 15 clinical sites. "The compelling...
Business Wire
Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse Vybrance Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules
Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse technology using proprietary Nanosecond Pulsed Field Ablation (nanosecond PFA or nsPFA) energy, today announced two milestones in the PRECISE-BTN clinical study evaluating the nPulse Vybrance Percutaneous Electrode System for the...
Business Wire
Why Pulse Biosciences Stock Popped Today
Key PointsAn analyst initiated coverage with an unambiguous buy recommendation...
Nasdaq News: Markets
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nano-PFA or nsPFA) technology, today announced that the Compensation Committee of its Board of Directors has granted equity awards to two new employees as equity inducement...
Business Wire
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nano-PFA or nsPFA) technology, today announced that the Compensation Committee of its Board of Directors has granted equity awards to five new employees as equity inducement...
Business Wire
Pulse Biosciences (PLSE) Q2 2026 Earnings Call Transcript
@media (max-width: 768px) {
.image-container {
width: 100% !important;
float: none !important;
margin: 0 0 1rem 0 !important;
}
}
Image source: The Mo...
Nasdaq News: Markets
Pulse Biosciences, Inc (PLSE) Reports Q2 Loss, Misses Revenue Estimates
Pulse Biosciences (PLSE) delivered earnings and revenue surprises of -16.13% and -38.00%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks